Literature DB >> 12641328

Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences.

E Swanepoel1, W Liebenberg, B Devarakonda, M M de Villiers.   

Abstract

Mebendazole, a broad spectrum anthelmintic drug, is practically insoluble in water and exists in three polymorphic forms, A, B, and C, of which C is pharmaceutically favoured. Since the dissolution of drugs from solid oral dosage forms can depend on the crystal form of the drug an attempt should be made while developing dissolution tests to set test parameters that are sensitive to changes in the crystal form. USP 24 describes 0.1 M hydrochloric acid containing 1.0% sodium lauryl sulphate (SLS) as the dissolution medium for mebendazole tablets. Results showed that the high concentration of sodium lauryl sulphate in the USP dissolution medium does not allow the use of this test to distinguish between the solubility differences of the three mebendazole polymorphs. By decreasing the amount of sodium lauryl sulphate in the dissolution medium clear differences in the dissolution rates of the three forms were observed. The most discriminating medium was 0.1 M HCl, containing no sodium lauryl sulphate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641328

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  2 in total

1.  Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets.

Authors:  Lisiane Bajerski; Rochele Cassanta Rossi; Carolina Lupi Dias; Ana Maria Bergold; Pedro Eduardo Fröehlich
Journal:  AAPS PharmSciTech       Date:  2010-04-07       Impact factor: 3.246

2.  Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and in Vitro Activity against Cryptococcus neoformans.

Authors:  Yogesh Sutar; Sophie R Fulton; Sagarkumar Paul; Sophie Altamirano; Susmit Mhatre; Hiwa Saeed; Pratikkumar Patel; Sudipta Mallick; Roopal Bhat; Vandana B Patravale; Harsh Chauhan; Kirsten Nielsen; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2021-09-01       Impact factor: 5.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.